ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 101 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,328 | -25.1% | 21,735 | +17.1% | 0.00% | – |
| Q2 2023 | $139,355 | +72.0% | 18,556 | +4.2% | 0.00% | – |
| Q1 2023 | $81,000 | +53542.4% | 17,807 | +32.7% | 0.00% | – |
| Q4 2022 | $151 | -99.9% | 13,416 | -8.0% | 0.00% | – |
| Q3 2022 | $140,000 | +28.4% | 14,581 | +8.6% | 0.00% | – |
| Q2 2022 | $109,000 | -66.6% | 13,428 | -30.2% | 0.00% | – |
| Q1 2022 | $326,000 | -4.1% | 19,237 | +21.6% | 0.00% | – |
| Q4 2021 | $340,000 | -69.4% | 15,820 | +5.3% | 0.00% | – |
| Q3 2021 | $1,110,000 | +64.4% | 15,028 | +21.7% | 0.00% | – |
| Q2 2021 | $675,000 | -7.8% | 12,345 | +24.3% | 0.00% | – |
| Q1 2021 | $732,000 | +66.7% | 9,932 | +95.0% | 0.00% | – |
| Q4 2020 | $439,000 | +220.4% | 5,094 | +42.8% | 0.00% | – |
| Q3 2020 | $137,000 | – | 3,568 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |